Novel Benzodiazepine Derivatives
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application 61/150,201, filed Feb 5, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,802,667 | Novel Benzodiazepine Derivatives In force · High confidence UsedRemaining | ImmunoGen, Inc. | In force | High confidence | ||
| US 8,809,320 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US 9,265,841 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US 9,550,787 | Novel Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | ||
| US 10,208,127 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US 10,947,315 | Novel Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | ||
| US 11,505,617 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US 8,426,402 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen Inc. | In force | High confidence | ||
| Application 15/371,738 | Novel Benzodiazepine Derivatives Abandoned Abandoned Oct 17, 2017 | ImmunoGen, Inc. | Abandoned | Abandoned Oct 17, 2017 | ||
| Application 15/676,316 | Novel Benzodiazepine Derivatives Abandoned Abandoned Aug 14, 2018 | ImmunoGen, Inc. | Abandoned | Abandoned Aug 14, 2018 |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
8 of these are in force and held by ImmunoGen, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.